Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01331447 · ClinicalTrials.gov registry record · NA
Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01331447: Completed NA study, sponsored by Roxane Laboratories.
NCT01331447 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01331447, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fasted conditions
Interventions
- DRUG exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-05 |
| Est. Completion | 2004-05 |
| Phase | NA |
What the finished NCT01331447 record still lists
NCT01331447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which exemestane is the first listed.
NCT01331447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01331447 about?
NCT01331447 is a clinical study titled "Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fasted conditions
What is the current status of trial NCT01331447?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2004-05. Estimated completion is 2004-05.
What interventions are being tested in trial NCT01331447?
The interventions under investigation include: exemestane (DRUG).
Who is sponsoring clinical trial NCT01331447?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01331447's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia